Evidence map›Paper›PMID 36073149›Full record

ReviewJournal of enzyme inhibition and medicinal chemistry2022

Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities.

Claudiu T Supuran

Open access · goldAbstract readReview
In one paragraph

Review in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Human Carbonic Anhydrase Inhibitors.ACS medicinal chemistry letters · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Claudiu T SupuranNEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Firenze, Italy.ORCID 0000-0003-4262-0323
Istituto Nazionale di Fisica Nucleare, Sezione di Firenze · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mitochondrial isoforms VA/VB of metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) are involved in metabolic processes, such as

Indexed as

Anti-Obesity AgentsCarbonic AnhydrasesCarbonic Anhydrase InhibitorsHumansObesitySulfonamidesAnti-Obesity AgentsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesSulfonamidesCarbonic anhydrasede novo lipogenesisfatty acid biosynthesismitochondrianatural productsobesityphenolssulphonamidestopiramatezonisamide

Identifiers

PMID36073149
PMCPMC9467601
OpenAlexW4294991963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.